Back to Search
Start Over
Association of Serum Sclerostin Level, Coronary Artery Calcification, and Patient Outcomes in Maintenance Dialysis Patients
- Source :
- Blood Purification. 51:260-269
- Publication Year :
- 2021
- Publisher :
- S. Karger AG, 2021.
-
Abstract
- Objective: The objective of this study is to investigate the association between the serum sclerostin, the coronary artery calcification (CAC), and patient outcomes in maintenance dialysis patients. Methods: We performed a prospective cohort study of 65 maintenance dialysis patients in 2014, including 39 patients on peritoneal dialysis and 26 on hemodialysis, and followed up for 5 years. Parameters of mineral metabolism including bone-specific alkaline phosphatase, fibroblast growth factor 23, sclerostin, and other biochemical factors were determined at the baseline. Meanwhile, the CAC score was analyzed by cardiac computed tomography. Results: Serum sclerostin in hemodialysis patients was significantly higher than that in peritoneal dialysis patients (632.35 ± 369.18 vs. 228.85 ± 188.92, p < 0.001). The patients with CAC were older, receiving hemodialysis, lower Kt/V, and had longer dialysis vintage, as well as higher levels of serum 25-(OH)-vit D and sclerostin. In multivariate logistic regression analysis, older age and lower Kt/V were risk factors for CAC. The area under the receiver operating characteristic curves for prediction of CAC by sclerostin was 0.74 (95% confidence interval 0.605–0.878, p = 0.03), and the cutoff value of sclerostin is 217.55 pg/mL with the sensitivity 0.829 and specificity 0.619. After 5 years of follow-up, 51 patients survived. The patients in the survival group had significantly lower age, sclerostin levels, and low CAC scores than the nonsurvival group. Old age (≥60 years, p < 0.001) and high CAC score (≥50 Agatston unit, p = 0.031) were significant risk factors for the patient survival. Conclusions: Sclerostin is significantly elevated in dialysis patients with CAC. But sclerostin is not a risk factor for CAC. After 5 years of follow-up, patients in the survival group are younger and have lower sclerostin levels and CAC scores. But sclerostin levels are not independent risk factors for high mortality in dialysis patients.
- Subjects :
- Fibroblast growth factor 23
medicine.medical_specialty
medicine.medical_treatment
Coronary Artery Disease
Gastroenterology
Peritoneal dialysis
chemistry.chemical_compound
Renal Dialysis
Internal medicine
medicine
Humans
Prospective Studies
Risk factor
Vascular Calcification
Prospective cohort study
Dialysis
business.industry
Hematology
General Medicine
Middle Aged
Confidence interval
chemistry
Nephrology
Sclerostin
Hemodialysis
business
Peritoneal Dialysis
Subjects
Details
- ISSN :
- 14219735 and 02535068
- Volume :
- 51
- Database :
- OpenAIRE
- Journal :
- Blood Purification
- Accession number :
- edsair.doi.dedup.....45a5ac9317a370712e113e697e1788d4
- Full Text :
- https://doi.org/10.1159/000516410